Cellectis’ CAR-T candidate shows positive effect in two early-stage leukemia studies
December 13, 2017
Servier and Pfizer's CAR-T candidate licensed from Cellectis shows positive effect in two early-stage leukemia studies.
Preliminary results were presented at ASH in Atlanta.
Preliminary results from two Phase 1 clinical trials assessing Servier and Pfizer's CAR-T candidate, UCART19, in leukemia patients showed a treatment effect. The first study, CALM, is evaluating UCART19 in adult patients with relapsed/refractory CD-19-positive B-cell acute lymphoblastic leukemia (B-ALL). Five of seven (71%) subjects achieved molecular remission at day 28 after treatment. Molecular remission is defined as negative minimal residual disease (MRD) (the number of residual leukemic cells remaining after treatment). The dose of UCART19 used in the first cohort was about 1/10 of that used in most autologous CAR-T studies. On the safety front, one mild case of acute graft-versus-host disease (GvHD) was observed. No severe neurotoxicity was observed. There was one death due to cytokine release syndrome (CRS) and neutropenic (abnormally low level of neutrophils) sepsis. All other cases of CRS were mild and manageable. The second study, PALL, is assessing UCART19 in pediatric patients with high-risk relapsed/refractory B-ALL. All five children treated achieved MRD negativity enabling them to proceed to allogeneic stem cell transplant. Only one mild case of GvHD was observed. No neurotoxicity occurred and CRSs were mostly mild and all were manageable. Servier and Pfizer are co-developing UCART19. Servier obtained exclusive global rights from Cellectis in November 2015.
Last News
- Alzheimer’s disease : Beyond the beta amyloid hypothesis
- Un monde posteuropéen : déjà une réalité ?
- PIB, Budget, Dépenses : Une mise au point.
Events
News archives
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012